Medical Doctor Program year 2021 Reported 2020–2021 Source: CMS Open Payments, 2026 publication

Bryan Updegraff

Clinical & Laboratory Dermatological Immunology Sun City, AZ Medical Doctor

NPI 1710971320 CMS profile 383509

14666 N Del Webb Blvd, Suite 60, Sun City, AZ 85351

Open in the dashboard

General payments

$140

2 records reported · program years 2020–2021

Research payments

$0

Paid to them · None reported · program years 2020–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Bryan Updegraff of Sun City, AZ is reported in the CMS Open Payments database as having received $140 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $15 1
2020 General $124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryan Updegraff
  • Clinical & Laboratory Dermatological Immunology median
  • Middle half of Clinical & Laboratory Dermatological Immunology
  • National median

In program year 2025, general payments to Bryan Updegraff were reported at $0. Among 32 Clinical & Laboratory Dermatological Immunology profiles paid that year, the median was $1,254 and the middle half received between $445 and $4,549.

Show as a table
Year Bryan Updegraff Clinical & Laboratory Dermatological Immunology median Middle half National median
2019 $0 $660 $180–$2,230 $163
2020 $124 $432 $119–$1,020 $114
2021 $15 $883 $156–$1,571 $132
2022 $0 $1,038 $99–$1,992 $149
2023 $0 $1,108 $199–$2,848 $160
2024 $0 $1,001 $122–$1,882 $164
2025 $0 $1,254 $445–$4,549 $169

Breakdown

Who paid General payments · program years 2020–2021
  1. OptiNose US, Inc. $124 1 payment
  2. Galderma Laboratories, L.P. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2021
  1. Food and Beverage $140 2 payments
Products named General payments · program years 2020–2021
  1. Xhance $124 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

547

Median for Dermatology: 534

Drug cost

$6,228

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluocinonide Generic 24 $1,397
Doxycycline Hyclate Generic 208 $1,282
Triamcinolone Acetonide Generic 123 $1,082
Hydrocortisone Generic 68 $682
Fluorouracil Generic 12 $637
Clobetasol Propionate Generic 19 $586
Montelukast Sodium Generic 32 $246
Fluticasone Propionate Generic 14 $121
Fluconazole Generic 24 $119
Cephalexin Generic 12 $52

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$271,587

Of which drugs: $986

Medicare patients

560

Average age 79

Services billed

11,148

248 women, 312 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 35%
Ischemic heart disease 31%
Diabetes 23%
Cancer 20%
COPD 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 85 433 $318
Injection, methylprednisolone acetate, 1 mg J1010 Office 57 2,531 $262
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 48 $221
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 19 76 $184

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical & Laboratory Dermatological Immunology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record